Feature | May 13, 2013

CREST Sub-Study Finds Angioplasty After Carotid Stenting Reduces Risk of Repeat Blockage

Minor adjustments during carotid artery interventions can reduce long-term restenosis at two-year follow-up and may lower risk of stroke complications

May 13, 2013 — For patients who received stents to restore blood flow through the main arteries supplying blood to the brain, inflating a tiny balloon inside the arteries after implantation of the stent reduced restenosis, or repeat blockages, of the treated arteries, making them less likely to reclose. Modifying the order in which carotid stenting and balloon angioplasty is performed could also alter risk of stroke complications, according to the investigators of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) sub-study presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2013 Scientific Sessions. 

CREST is the largest, prospective randomized study that compared angioplasty and stenting of the carotid artery in the neck to surgery (carotid endarderectomy), the standard treatment. Carotid stenting is currently only available as a treatment option for patients who cannot undergo surgery. The objective of this sub-study was to evaluate whether undergoing angioplasty post-carotid stenting increases the risk of complications such as stroke.

“Carotid stenting is the subject of ongoing research because it provides a less invasive treatment option, which is often necessary for patients who are too sick to undergo surgery,” said Mahmoud B. Malas, M.D., lead author of the sub-study and associate professor of surgery at Johns Hopkins University and chief of endovascular surgery at Johns Hopkins Bayview Medical Center in Baltimore. “These results show performing balloon angioplasty after stenting significantly reduced the risk of those same arteries narrowing again, but may also increase, though not significantly, the risk of stroke.”

Of 1,109 patients in CREST who underwent carotid artery stenting, 69 patients underwent balloon deployment before the stent was implanted, 344 underwent balloon deployment after the stent was implanted and 696 patients had balloon angioplasty before and after the stent was implanted.

Researchers found the risk of restenosis was reduced by 64 percent simply by expanding a tiny balloon after the stent was placed in the diseased artery rather than before it was implanted. However, the group that underwent angioplasty after the stent had a larger number of strokes compared to the group who received angioplasty only prior to the stent, but that number was not statistically significant.

Results of the CREST trial also showed historically the lowest incidence of stroke as a complication of stenting and balloon angioplasty, regardless of the order. “We actually had too few complications to make any statistically significant assessment about risk of stroke between the different ballooning methods,” explained Malas.

An estimated 83.6 million adults in the United States, about one in three, currently have some form of cardiovascular disease. An estimated 6.8 Americans are expected to suffer from stroke this year alone, according to 2013 statistics from the American Heart Association.

Balloon angioplasty is a common treatment for atherosclerosis, a hardening or narrowing of major arteries throughout the body. The carotid arteries are the main arteries supplying oxygen- and nutrient-rich blood to the brain directly from the aorta as it ascends from the heart. If these essential arteries become blocked, or stenotic, there is a higher risk of stroke because of small debris breaking off from the diseased artery and traveling to the brain. Angioplasty and stenting is performed by interventional cardiologists and vascular surgeons and involves guiding tiny instruments with medical imaging through a small incision in the groin area through major blood vessels to the affected artery—in this case the carotid arteries in the neck. Once in position, a small mesh coil called a stent is implanted inside the artery.

Malas reports no relevant conflicts of interest.

For more information: www.scai.org

Related Content

Biotronik, BioMonitor 2 implantable cardiac monitor, BioInsight clinical study, first patients enrolled
News | Implantable Cardiac Monitor (ICM)| January 20, 2017
Biotronik has enrolled the first patients in the BioInsight clinical study evaluating the safety and feasibility of...
ICDs, non-ischemic cardiomyopathy, University of Alabama at Birmingham study, Circulation
News | Implantable Cardioverter Defibrillators (ICD)| January 18, 2017
A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-...
stress, brain activity, cardiovascular risk, PET-CT, MGH, ISSMS, The Lancet study
News | Cardiac Diagnostics| January 18, 2017
A study led by Massachusetts General Hospital (MGH) and Icahn School of Medicine at Mount Sinai (ISSMS) investigators...
ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillators (ICD)| January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
University of Utah, Frank Sachse, heart failure, LVAD implantation, left ventricular assist device, biomarker, t-system

Two patients may seem equally sick based upon clinical measures, but differences in their heart physiology could predict who has the potential to recover from heart failure. A study carried out by scientists at the University of Utah finds that patients whose hearts have flattened t-tubules have a decreased chance of showing signs of recovery after implanting a mechanical heart pump. Ordinarily, t-tubules in the heart are long, thin, and rounded. Image courtesy of Frank Sachse.

News | Cardiac Diagnostics| January 17, 2017
Investigators at the University of Utah have identified distinct differences in the hearts of advanced heart failure...
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
MD Buyline, James Laskaris, four medical technology innovations, very near future
Feature | Cardiac Imaging| January 17, 2017
James Laskaris, emerging technology analyst at MD Buyline, recently offered his perspective on new medical technology...
St. Jude Medical, Amplatzer Amulet LAA Occluder, observational study, TCT 2016
News | Left Atrial Appendage (LAA) Occluders| November 03, 2016
St. Jude Medical Inc. presented favorable results from the largest observational study to date of the company’s...
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
congenital heart patients, cardiac cath lab, anesthesia sedation practices, joint document, SCAI, SPA, CCAS
News | Congenital Heart| November 03, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the...
Overlay Init